BioNTech is a biotechnology company based in Germany, known for its work in the development of mRNA-based therapeutics and vaccines. Founded in 2008, BioNTech gained international prominence for its role in developing one of the first COVID-19 vaccines in collaboration with Pfizer. The company’s innovative approach utilizes messenger RNA (mRNA) technology to instruct cells to produce proteins that can trigger an immune response, thereby providing protection against various diseases. In addition to its work on vaccines, BioNTech is also involved in developing treatments for cancer and other infectious diseases through personalized medicine strategies. Its focus on cutting-edge research positions BioNTech as a significant player in the biotechnology and pharmaceutical industries.
BioNTech shifts focus from COVID-19 vaccines to mRNA-based cancer therapies, aiming for market entry by 2026. Earnings per share fell to €1.08, surpassing expectations of €0.407, though declined from €1.90…